Protocol Ledger

NCT07322003 · Phase III · RECRUITING

Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS

Interventional Phase III clinical trial protocol NCT07322003 sponsored by Prilenia in Neurology, Psychiatry, and Pain, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-02-01 Enrollment: 500 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07322003
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)500 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07322003
Protocol FieldVerified Registry Value
NCT IdentifierNCT07322003
Consolidated Lead SponsorPrilenia
Therapeutic Condition CohortNeurology, Psychiatry, and Pain
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment500 participants (ESTIMATED)
Registered Start Date2026-02-01
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Neurology, Psychiatry, and Pain Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI